(RTTNews) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial weight loss and reductions in blood sugar levels in a Phase 2b trial involving 367 adults with obesity or overweight and type 2 diabetes. After 48 weeks, participants receiving the highest-dose combination of eloralintide 9 mg and tirzepatide 15 mg lost an average of 54.1 pounds, or 23.3 percent of body weight, while A1C declined by 2.9 percent. By comparison, tirzepatide 15 mg alone resulted in an average weight loss of 34.4 pounds, or 14.8 percent, and a 2.4 percent A1C reduction.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。